key: cord-0929632-waaqk841
authors: Qaseem, Amir; Yost, Jennifer; Etxeandia-Ikobaltzeta, Itziar; Forciea, Mary Ann; Abraham, George M.; Miller, Matthew C.; Obley, Adam J.; Humphrey, Linda L.
title: What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 1)
date: 2021-03-16
journal: Ann Intern Med
DOI: 10.7326/m20-7569
sha: 55d1bf361bd7d432663c3d4f42888312387b0f4d
doc_id: 929632
cord_uid: waaqk841

Description: The widespread availability of SARS-CoV-2 antibody tests raises important questions for clinicians, patients, and public health professionals related to the appropriate use and interpretation of these tests. The Scientific Medical Policy Committee (SMPC) of the American College of Physicians developed these rapid, living practice points to summarize the current and best available evidence on the antibody response to SARS-CoV-2 infection, antibody durability after initial infection with SARS-CoV-2, and antibody protection against reinfection with SARS-CoV-2. Methods: The SMPC developed these rapid, living practice points based on a rapid and living systematic evidence review done by the Portland VA Research Foundation and funded by the Agency for Healthcare Research and Quality. Ongoing literature surveillance is planned through December 2021. When new studies are identified and a full update of the evidence review is published, the SMPC will assess the new evidence and any effect on the practice points. Practice Points: Practice Point 1: Do not use SARS-CoV-2 antibody tests for the diagnosis of SARS-CoV-2 infection. Practice Point 2: Antibody tests can be useful for the purpose of estimating community prevalence of SARS-CoV-2 infection. Practice Point 3: Current evidence is uncertain to predict presence, level, or durability of natural immunity conferred by SARS-CoV-2 antibodies against reinfection (after SARS-CoV-2 infection).

The widespread availability of SARS-CoV-2 antibody tests raises important questions for clinicians, patients, and public health professionals related to the appropriate use and interpretation of these tests. However, currently little is known about the relationship between SARS-CoV-2 antibodies and natural immunity. The potential for natural immunity to SARS-CoV-2 infection stems from the activation of B lymphocytes (humoral or antibody-mediated immunity) and T lymphocytes (cellular immunity). However, like with other viruses, the relationship between antibodies and natural immunity may vary on the basis of differences in the level and duration of antibodies produced as well as viral mutations of the infection. When persons are infected with SARS-CoV-2, uncertainty exists about whether the antibodies produced (IgM, IgG, IgA, or neutralizing) are protective against reinfection, and if so, for how long what levels of antibodies are needed for such protection (1) . In addition, because antibodies to other coronaviruses have been shown to decline over time, how long such protection against reinfection may last also needs to be determined (2) . As a step toward better understanding the immune response to SARS-CoV-2, the Scientific Medical Policy Committee (SMPC) of the American College of Physicians (ACP) developed these practice points on the basis of key questions related to the antibody-mediated natural immunity after SARS-CoV-2 infection. This article does not evaluate cellular immunity or artificial immunity conferred by vaccines, both of which are important areas of research.

The SMPC developed these rapid, living practice points ( Table 1 ) on the basis of a rapid and living systematic evidence review done by the Portland VA Research Foundation and funded by the Agency for Healthcare Research and Quality (3, 4) . The details of our process can be found in the Appendix (available at Annals.org). This version of the practice points is based on an initial search to 4 August 2020 that was subsequently revised and updated through 15 December 2020. It was approved by ACP's Executive Committee of the Board of Regents on behalf of the Board of Regents on 22 February 2021 and submitted to Annals of Internal Medicine on 22 February 2021. Ongoing literature surveillance is planned through December 2021. The target audience for these practice points includes clinicians, patients, the public, and public health officials. The target patient population includes adults who have been previously infected with SARS-CoV-2. Table 2 presents clinical considerations, the Figure and Table 3 summarize current evidence, and Table 4 identifies additional evidence gaps. The Appendix Table  ( Evidence is emerging about the antibody response to SARS-CoV-2 and its durability after initial infection with SARS-CoV-2 as well as protection against future reinfection with SARS-CoV-2. The following practice points are based on current, best available evidence: Practice Point 1: Do not use SARS-CoV-2 antibody tests for the diagnosis of SARS-CoV-2 infection. Practice Point 2: Antibody tests can be useful for the purpose of estimating community prevalence of SARS-CoV-2 infection. Practice Point 3: Current evidence is uncertain to predict presence, level, or durability of natural immunity conferred by SARS-CoV-2 antibodies against reinfection (after SARS-CoV-2 infection).

In the face of uncertainty, patients with SARS-CoV-2 infection, those with a history of SARS-CoV-2 infection, and the public should follow infection prevention and control procedures to slow and reduce the transmission of SARS-CoV-2 (maintain physical distance; wear face coverings, such as surgical or cloth masks, in settings where physical distancing is not possible; use masks appropriately; self-isolate; quarantine; practice frequent hand hygiene [use soap and water or alcohol-based hand rub]; cover cough and sneezes using a bent elbow or paper tissue; refrain from touching the face; and regularly disinfect frequently touched surfaces) (5, 6) .

The relationship between the development of antibodies after SARS-CoV-2 infection and the risk for reinfection has not been established (3, 4) . Although SARS-CoV-2 serologic tests detect IgM, IgG, and IgA immunoglobulins, the tests may also give a positive result due to cross-reactivity with antibodies to other coronaviruses (3, 4) . Evidence considers serologic tests that were approved and for which emergency use authorization had not been revoked by the U.S. Food and Drug Administration as of 5 August 2020 (3, 4) . SARS-CoV-2 serologic tests vary in accuracy, and there is insufficient evidence on the association between the use of different tests and the presence of detectable antibodies. These practice points evaluate only the antibody-mediated natural immunity response and do not address the role of other important natural immune responses, such cell-mediated immunity or artificial immunity conferred by vaccines.

Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2

Practice Point 2: Antibody tests can be useful for the purpose of estimating community prevalence of SARS-CoV-2 infection.

Studies included in the evidence review focused on evaluating the trends in types of antibodies and their levels after symptom onset or confirmation of SARS-CoV-2 infection with a positive RT-PCR test result. Evidence from studies evaluating community prevalence in antibody response showed that patients develop an immune response after SARS-CoV-2 infection. This is evidenced by detectable IgA antibodies in most patients (low certainty), IgM in most patients (moderate certainty), IgG in nearly all patients (moderate certainty), and neutralizing antibodies in nearly all patients (low certainty). The antibody prevalence and levels may vary over time by certain patient characteristics (for example, age, sex, and race/ethnicity) and disease factors (for example, presence of symptoms and severity) (low certainty). The timing from symptom onset or PCR-confirmed infection of when antibodies first become detectable and the level at which they remain detectable vary depending on the type of antibody. At or around peak level, IgM, IgG, IgA, and neutralizing antibodies are estimated to be detectable in approximately 80%, 95%, 83%, and 99% of patients, respectively, after symptom onset or PCRconfirmed infection. Despite variation, each of these antibody types has its peak level on average between 20 and 31 days after symptom onset or PCR-confirmed infection. Evidence shows that antibodies may persist over time; IgM antibodies were detected up to 115 days (moderate certainty), IgG antibodies were detected up to 120 days (moderate certainty), IgA antibodies were detected up to 140 days (low certainty), and neutralizing antibodies were detected up to 152 days (low certainty).

Given that not all patients develop detectable antibodies early in the course of the infection and that the presence and levels may vary by patient and disease characteristics, antibody tests should not be used for the diagnosis of SARS-CoV-2 infection. It is also important for clinicians and patients to keep in mind that SARS-CoV-2 antibody test results may be falsely positive due to cross-reactivity with antibodies of other coronaviruses (74, 75). Furthermore, although a complete assessment of diagnostic accuracy of various antibody tests was beyond the scope of the evidence review, characteristics (for example, sensitivity, specificity, and accuracy) varied substantially among the antibody tests used in included studies (3, 4) . Such variation can contribute to false-negative and false-positive test results and ultimately wrong conclusions (76, 77).

However, for the purposes of estimating community prevalence of SARS-CoV-2 infection, antibody testing is a feasible option, keeping in mind that antibody levels peak roughly 3 to 5 weeks after symptom onset or PCR * Insufficient certainty of evidence: confidence is inadequate to assess the likelihood of benefit (benefit minus harm) of an intervention or its effect on a health outcome. Low certainty of evidence: confidence in the effect is limited because the true effect may be substantially different from the estimated effect. Moderate certainty of evidence: confidence in the effect is moderate because the true effect is likely close to the estimated effect, but there is a sizable possibility that it is substantially different. High certainty of evidence: confidence that the true effect is close to the estimated effect. Assessments regarding antibody prevalence were focused on results from seroprevalence, cross-sectional, and cohort studies, rather than on results from immunoassay validation studies (which provide less reliable estimates). For all other outcomes of interest, results from all studies were incorporated into strength of evidence assessments (3, 4) . † "Nearly all" refers to greater than 90% of the participants across studies, "most" refers to more than half of the participants across studies, and "some" refers to less than half of the participations across studies.

Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 diagnosis. Also, the usability and interpretation of SARS-CoV-2 antibodies will need to be evaluated in persons vaccinated against COVID-19, as vaccination will also affect the development of SARS-CoV-2 antibodies.

Practice Point 3: Current evidence is uncertain to predict presence, level, or durability of natural immunity conferred by SARS-CoV-2 antibodies against reinfection (after SARS-CoV-2 infection).

Current evidence is limited about natural immunity conferred by SARS-CoV-2 antibodies. As discussed earlier, asymptomatic or symptomatic patients may develop an antibody response consistent with natural immunity after having SARS-CoV-2 infection, but key individuallevel differences depend on such variables as COVID-19 disease severity, patient factors, types of antibodies and amount developed, and how long the antibodies last. This is an area of rapidly emerging new evidence. No identified evidence directly evaluates the association between antibodies and natural immunity, although 2 studies are in progress (7, 78) . In the evidence review, a study (8) of hospitalized patients with COVID-19 (n = 47) reported a potential case of reinfection during the "convalescence stage" of the disease in 1 patient who did not have detectable IgM or IgG antibodies at 4-week followup. However, the study was not designed to determine whether antibodies confer immunity. Evidence does show that there are detectable levels of IgA antibodies in most patients (low certainty), IgM in most patients (moderate certainty), IgG in nearly all patients (moderate certainty), and neutralizing antibodies in nearly all patients (low certainty). Evidence also shows that IgG antibodies probably remain detectable for at least 120 days (moderate certainty) and neutralizing antibodies may remain detectable for at least 152 days (low certainty). The antibody prevalence and levels over time may vary by certain patient characteristics (for example, age, sex, and race/ethnicity) and disease factors (for example, presence of symptoms and severity) (low certainty). The evidence review also identified 3 longitudinal studies (indirect evidence) that used serologic rather than RT-PCR testing as the index test and, thus, did not meet the inclusion criteria. These studies suggest that antibody presence may be associated with natural immunity (78) (79) (80) (81) ; however, the evidence review has not critically appraised them. Given that there is no direct evidence to inform the question of reinfection, we will consider modifying future searches to formally incorporate additional sources of indirect evidence, including these studies.

Evidence is uncertain (insufficient) about the unintended consequences of antibody testing.

Given limited knowledge about the association between antibody levels and natural immunity, patients with SARS-CoV-2 infection and those with a history of SARS-CoV-2 infection should follow recommended infection prevention and control procedures to slow and reduce the transmission of SARS-CoV-2 (5, 6). Note: The practice points are developed by the SMPC of the ACP. The practice points are guides only and may not apply to all patients and all clinical situations. All practice points are considered automatically withdrawn or invalid 5 years after publication, or once an update has been issued.

Financial Statement: Financial support for the development of the Practice Points comes exclusively from the ACP operating budget.

Disclosures: All financial and intellectual disclosures of interest were declared, and potential conflicts were discussed and managed. Dr. Jokela participated in discussion of the practice points but was recused from authorship and voting due to a moderate-level conflict of interest (authored recent relevant publications). Dr. Marcucci participated in the discussion of the practice points but was recused from authorship and voting due to a moderate-level conflict of interest (author of relevant systematic review [forthcoming]). A record of disclosures of interest and management of conflicts is kept for each SMPC meeting and conference call and can be viewed at www .acponline.org/about-acp/who-we-are/leadership/boards-committees -councils/scientific-medical-policy-committee/disclosure-of-interests -and-conflict-of-interest-management-summary-for-scientific-medical -policy. Disclosures can also be viewed at www.acponline.org /authors/icmje/ConflictOfInterestForms.do?msNum=M20-7569. and includes members with expertise in epidemiology, evidence synthesis, health policy, and guideline development. In addition to contributing clinical, scientific, and methodological expertise, Clinical Policy staff provided administrative support and liaised among the SMPC, the evidence review funding entity and evidence team, and the journal. Clinical Policy staff and the SMPC reviewed and prioritized potential topic suggestions from ACP members, SMPC members, and ACP governance. A committee subgroup, including the SMPC chair, worked with staff to draft the key questions and led the development of the practice points. Clinical Policy staff worked with the subgroup and an independent evidence review team to refine the key questions and determine appropriate evidence synthesis methods for each key question. Via conference calls and e-mail, Clinical Policy staff worked with the committee subgroup to draft the practice points on the basis of the results of the rapid and living systematic evidence review. The full SMPC reviewed and approved the final practice points. Before journal submission, ACP's Executive Committee of the Board of Regents also reviewed and approved the practice points on behalf of the ACP Board of Regents. The evidence review team is planning ongoing literature surveillance at least through December 2021. When no new studies are identified, the SMPC will publish a comment on the most recent version of the practice points that indicates the date of the last search and that no new studies were identified. When new studies are identified but previous conclusions remain unchanged, the SMPC will publish an update alert letter that briefly summarizes the new evidence and updates the rationale and evidence tables for the practice points. When new studies are identified and a full update of the evidence review is published, the SMPC will assess the new evidence and reaffirm (via update alert letter) or revise and modify (via new version) the practice points. The SMPC will continually evaluate the priority level of each living topic and may decide to retire a topic early from living status if it determines that the topic is no longer considered a priority for decision making, if there is confidence that the conclusions are not likely to change with the emergence of new evidence or affect practice, or when it is unlikely that new evidence will emerge (82). 

What we know about the COVID-19 immune response: the latest on COVID-19 immunity & the current global situation. Accessed at www.who.int/docs/default-source /coronaviruse/risk-comms-updates/update-34-immunity-2nd.pdf?sfvrsn =8a488cb6_2 on 11

The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection

Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living review

Antibody response following SARS-CoV-2 infection and implications for immunity: a rapid living review. (Prepared by the Portland VA Research Foundation under Contract No

Posted final reports are located on the Effective Health Care Program search page

Advice on the use of masks in the context of COVID-19: interim guidance

Guidance for wearing masks

Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

A comparative study of the laboratory features of COVID-19 and other viral pneumonias in the recovery stage

Humoral immune response to SARS-CoV-2 in Iceland

SARS-CoV-2 seroprevalence among parturient women in Philadelphia

SARS-CoV-2 infections and serologic responses from a sample of U.S. Navy service members-USS Theodore Roosevelt

Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

Efficacy of a test-retest strategy in residents and health care personnel of a nursing home facing a COVID-19 outbreak

Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France

Detection of IgM and IgG antibodies in patients with coronavirus disease 2019

Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with pneumonic COVID-19 patients

Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019

Patterns of IgG and IgM antibody response in COVID-19 patients

Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Factors affecting antibody response to SARS-CoV-2 in patients with severe COVID-19

Stock da Cunha T, Gomá-Garc es E, Avello A, et al. The spectrum of clinical and serological features of COVID-19 in urban hemodialysis patients

Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs

Dysfunction of adaptive immunity is related to severity of COVID-19: a retrospective study

Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19

Dynamic anti-spike protein antibody profiles in COVID-19 patients

Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers

Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production

SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered

Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 cases and close contacts

Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection

Study of antibody-based rapid card test in COVID-19 patients admitted in a tertiary care COVID hospital in Southern Rajasthan

Temporal antibody responses to SARS-CoV-2 in patients of coronavirus disease 2019

Dynamics of CD4 T cell and antibody responses in COVID-19 patients with different disease severity

Factors of severity in patients with COVID-19: cytokine/chemokine concentrations, viral load, and antibody responses

Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity

Lack of antibodies to SARS-CoV-2 in a large cohort of previously infected persons

Sustained SARS-CoV-2 nucleocapsid antibody levels in nonsevere COVID-19: a populationbased study

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

IgG seroconversion and pathophysiology in severe acute respiratory syndrome coronavirus 2 infection

Anti-SARS-CoV-2 antibody responses in convalescent plasma donors are increased in hospitalized patients; subanalyses of a phase 2 clinical study. Microorganisms

Screening for SARS-CoV-2 antibodies in convalescent plasma (CCP) in Brazil: results from a voluntary convalescent donor program

Singapore 2019 Novel Coronavirus Outbreak Research team. Viral dynamics and immune correlates of COVID-19 disease severity

Yale IMPACT Research Team. Sex differences in immune responses that underlie COVID-19 disease outcomes

Analysis of the application value of serum antibody detection for staging of COVID-19 infection

Detection of IgG antibody during the follow-up in patients with COVID-19 infection

Healthcare staff perceptions & misconceptions regarding antibody testing in the United Kingdom: implications for the next steps for antibody screening

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Changes in serum virus-specific IgM/IgG antibody in asymptomatic and discharged patients with reoccurring positive COVID-19 nucleic acid test (RPNAT)

Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/ IgG

Saint-Louis CORE (COvid REsearch) group. Evaluation of the COVID-19 IgG/IgM rapid test from Orient Gene Biotech

Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2

IgM and IgG antibodies: an Italian experience

Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2

Performance of severe acute respiratory syndrome coronavirus 2 antibody assays in different stages of infection: comparison of commercial enzyme-linked immunosorbent assays and rapid tests

Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19

Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity

Combination of serological total antibody and RT-PCR test for detection of SARS-COV-2 infections

Antibody detection and dynamic characteristics in patients with coronavirus disease 2019

Diagnostic performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus disease 2019

Analysis of adjunctive serological detection to nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis. Int Immunophar-macol

A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients

PCV21 cost-effectiveness analysis of plus aspirin vs placebo plus aspirin in the treatment of ischemic stroke based on a randomized clinical trial

Infectious Diseases Society of America. IDSA COVID-19 antibody testing primer

Centers for Disease Control and Prevention. Using antibody tests for COVID-19

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate

The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers

Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2

Current Author Addresses: Dr. Qaseem: American College of Physicians

Etxeandia-Ikobaltzeta: 1 Santa Margarita Hospital Street, Ground Floor

Saint Vincent Hospital, 123 Summer Street

Penn Medicine Radnor, 250 King of Prussia Road

Obley: Oregon Health & Science University, 3030 SW Moody

Portland Veterans Affairs Medical Center and Oregon Health & Science University, 3710 SW U.S. Veterans Hospital Road

Critical revision of the article for important intellectual content: A

Median, 20 d (range, 10 to 35 d) Starts to decline (n = 2413) (19, 23, 29, 30

Median, 60 d (range, 30 to 100 d) Latest detected (9): 120 d Moderate IgA 6 (2234) Earliest detected (n = 40) (62): 11 d Peak (n = 632) (42, 51): Range, 16 to 30 d Starts to decline (n = 1977

The SMPC, in collaboration with staff from ACP's Department of Clinical Policy, developed these practice points on the basis of a rapid and living systematic evidence review done by the Portland VA Research Foundation and funded by the Agency for Healthcare Research and Quality (3, 4) . The SMPC comprises 11 internal medicine physicians representing various clinical areas of expertise and 1 public (nonclinician) member

Appendix (20) No difference for neutralizing antibody activity (14) Higher prevalence among older adults, but not statistically significant (56) No difference in IgG seronegative status (40) No difference in seroconversion rates by patient age (43) Antibody levels (n = 5567) Among recovered group, antibody levels were higher in older persons (9) No difference in IgM or IgG levels (29) Statistically significant correlation between IgG levels and age (32) Patients with older age had higher IgM and IgG antibody levels (36) No difference in the antibody response by age (37) IgG levels significantly higher in older patients (56) Age >70 y associated with higher IgG concentration (43) Age ≥50 y correlated with higher IgG titers (44)

Appendix (20) No association with neutralizing antibody (14) Nonstatistically significant finding of higher prevalence among men (56) No difference (40) No difference (43) Low Antibody levels (n = 3995) Among recovered group, pan-Ig anti-S1-RBD and IgA anti-S1 levels were lower in female patients (9) IgM titers were higher in male patients than female patients; no difference was observed for IgG (29) No difference in IgG or IgM (36) No difference (37) No difference in antibody concentrations (43) No difference in IgG or IgM (47) No difference (44) No difference (45) Race/ethnicity Summary: Non-White race may be associated with higher antibody prevalence or levels

Antibody prevalence (n = 2547) Non-Hispanic Whites were more than twice as likely as non-Hispanic Blacks to lack IgG antibodies (40) Low Antibody levels (n = 177) Higher IgG antibody concentrations were associated with non-White race (43) Preexisting comorbid conditions no difference related to preexisting diabetes, hypertension, chronic heart disease, chronic kidney disease, chronic liver disease, or chronic obstructive pulmonary disease (40) Insufficient Antibody levels (n = 3617) Among recovered group, BMI was associated with higher antibody levels; tobacco use was associated with lower antibody levels (9) IgG titers were significantly associated with diabetes (36) No significant differences in antibody concentrations when stratifying patients by comorbid conditions (hypertension, type 2 diabetes, obesity, and chronic kidney disease) (39) No significant difference in IgM or IgG titers by underlying disease (29) No correlations between initial virus-specific IgG level and BMI (32) Weight was positively correlated with IgM, IgG, and IgA titers (45) Continued on following page Appendix Disease severity was associated with a delay in detectable antibodies compared with cases of less severe disease (8, 19, 28, 36, 56) Disease severity was associated with earlier seroconversion (46) Variation in antibody levels (n = 8228): Association between disease severity and higher antibody levels (9, 17, 19, 23, 27, 28, 32-34, 36, 38, 39, 42, 44, 46, 48, 63) Disease severity is associated with lower antibody levels (22, 29, 31); finding was specific to patients with critical illness (29, 31) Mixed findings (15) No difference (25, 26, 66, 71) Symptoms Summary: The presence or absence of symptoms may be associated with higher antibody prevalence and levels Low 9 (4793) Presence of symptoms associated with higher antibody prevalence and levels (n = 2155) (32, 40) Inconsistent results (n = 2638) (9, 14, 43, 44, (65) (66) (67) Immunoassay tests

Insufficient 10 (1996) For an overview of the immunoassay tests used in the included studies (i.e., immu noassay manufacturer information, performance characteristics, and authorization status in the United States and Europe), please see Supplement Table 4 in the accompanying evidence report (3, 4) Unintended consequences of antibody testing Physical distancing and behaviors 1 (84) Among health care workers in the United Kingdom who had SARS-CoV-2 serologic testing answering how they would react to different test results (50) 11% said that positive antibody test results would mean "social distancing is less important" for them 30% said that they would be less likely to catch COVID-19 in the future 31% said that they would be happier to visit friends and relatives Insufficient BMI = body mass index; NA = not applicable; RBD = receptor-binding domain; RT-PCR = reverse transcriptase polymerase chain reaction. * Insufficient certainty of evidence: confidence is inadequate to assess the likelihood of benefit (benefit minus harm) of an intervention or its effect on a health outcome. Low certainty of evidence: confidence in the effect is limited because the true effect may be substantially different from the estimated effect. Moderate certainty of evidence: confidence in the effect is moderate because the true effect is likely close to the estimated effect, but there is a sizable possibility that it is substantially different. High certainty of evidence: confidence that the true effect is close to the estimated effect. Assessments regarding antibody prevalence were focused on results from seroprevalence, cross-sectional, and cohort studies, rather than on results from immunoassay validation studies (which provide less reliable estimates). For all other outcomes of interest, results from all studies were incorporated into strength of evidence assessments (3, 4) . † Calculation based on results of studies that evaluated antibody prevalence close to its estimated peak (20, 25 , and 30 d after symptom onset or positive PCR test result for SARS-CoV-2 for IgM, IgG, and neutralizing antibodies, respectively), excluding studies that did not provide estimates within plus or minus 10 d of the peak. If studies reported antibody prevalence as measured by more than 1 immunoassay, the highest prevalence estimate was used. Calculations do not include results of total antibody immunoassays (IgM and IgG) (3, 4) . ‡ The results of 2 studies (33, 45) were not reported in a way that could be synthesized with other studies. § The results of 3 studies (15, 23, 42) were not reported in a way that could be synthesized with other studies.